CytoSorbents Corporation (CTSO)

[pharmeng]

The revenue is promising, good to see growth back on track. The market cap has come down quite a bit, so valuation is a bit more rationale.

I am still puzzled by their stubbornness not to run a sepsis trial. The payer situation has only gotten tougher in the last year, so I don't know why they thought they could get away with a hard endpoint. Especially since reducing IL-6 level has never been correlated with improved survivals. Increased IL-6 level is seen with worse survival, but reducing it may not necessarily be the key.